SHANGHAI – Beijing-based Canbridge Life Sciences Inc. is a biotech that seeks to bring Western innovation to Chinese patients who have few if any treatment options. That licensing strategy has led it to sign a deal with Apogenix GmbH, of Heidelberg, Germany, for lead candidate APG101, an onco-immunotherapy targeting the CD95 ligand for a highly lethal and difficult to treat type of brain cancer, glioblastoma multiforme.